CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop an innovative technology for the mass production of personalized induced pluripotent stem cells (iPSCs) using an artificial intelligence-guided microfluidic device. The goal is to enhance cancer immunotherapies and tissue regeneration by ensuring standardized, cost-effective production of a…
Induced pluripotent stem cell (iPSCs) can be differentiated into any cell type of the body and transplanted without rejection.
The potential of iPSCs to cure health problems including degenerative diseases, cancer, cancer therapy associated disease and defective tissues, is unprecedented in history.
However, the current methodologies prohibit standardized production of person's own (autologous) iPSCs, hence rejection is taking place and the therapeutic promise is not fulfilled.
Our consortium se…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Greece, ATHENS
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Latvia, Riga
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Austria, Wien
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
